Explore ›
Finding
Finding
adverse
Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.
| Effect size | HR 5.41 (HCT vs chemotherapy) |
| CI | 95% CI 3.23–9.06 |
| Follow-up | 5 years |
| Comparator | Pediatric-style post-remission chemotherapy (CALGB 10403) |
| Effect summary | adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06 |
| Adverse events | non-relapse mortality 29% vs 8% |
Connected entities
Conditions
Outcomes
Populations
Source
PMC8257494
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: Analysis from CALGB 10403 and the CIBMTR